SCHEDULE 13G/A: Bain Capital Life Sciences Discloses 4.1% Stake in Century Therapeutics

Bain Capital Life Sciences Opportunities III, LP has filed an amendment disclosing its beneficial ownership of 4.1% of Century Therapeutics, Inc.'s common stock as of September 30, 2025.

Summary

• Bain Capital Life Sciences Opportunities III, LP (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Century Therapeutics, Inc.
• As of September 30, 2025, the Reporting Person beneficially owned 3,538,609 shares of Century Therapeutics, Inc. Common Stock.
• This ownership represents approximately 4.1% of the issuer's outstanding Common Stock.
• The percentage is calculated based on 86,389,098 shares of Common Stock issued and outstanding as of August 1, 2025, as reported by Century Therapeutics in its Form 10-Q for the quarter ended June 30, 2025.
• The Reporting Person, along with related Bain Capital Life Sciences Entities, shares both voting and dispositive power over these shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, the continued significant ownership by a respected institutional investor like Bain Capital Life Sciences can be interpreted as a positive signal for Century Therapeutics, suggesting confidence in the company's prospects, even if the stake is below the 5% threshold for active influence.

Positives

• A significant investment by a reputable life sciences-focused private equity firm like Bain Capital Life Sciences can be viewed as a vote of confidence in Century Therapeutics' long-term potential and strategic direction.
• The disclosure of a 4.1% stake indicates a substantial, albeit passive, interest from a sophisticated institutional investor.

Negatives

• The filing itself does not contain any negative financial or operational information about Century Therapeutics, Inc.

Risks

• The filing does not detail specific risks related to Century Therapeutics, Inc.'s operations or financial health. It is a disclosure of beneficial ownership by an investor.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Century Therapeutics, Inc. or the Reporting Person regarding future performance or strategic plans.

Industry Context

This Schedule 13G filing indicates that a prominent life sciences investment firm, Bain Capital Life Sciences, maintains a significant, albeit passive, stake in Century Therapeutics. Such disclosures are common in the biotechnology sector, where institutional investors often take positions in companies with promising pipelines. While not an active investment announcement, it signals continued interest from a major player in the healthcare investment landscape.

Comparison to Industry Standards

• A 4.1% stake is a notable position for an institutional investor, though it falls below the 5% threshold that would typically trigger an initial Schedule 13D filing (which implies intent to influence management) or a new 13G filing if it were the first time crossing 5%. As an amendment, it updates a previously disclosed position.
• Bain Capital Life Sciences is a well-known investor in the biotechnology and pharmaceutical sectors, with a portfolio that includes companies like Cerevel Therapeutics, Recursion Pharmaceuticals, and SpringWorks Therapeutics. Their continued holding in Century Therapeutics aligns with their strategy of investing in innovative life sciences companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor may instill confidence among existing shareholders and potentially attract new investors, signaling external validation of the company's value.
• Management: While Bain Capital Life Sciences certifies it does not intend to influence control, their presence as a large shareholder means management will likely be aware of their investment and potential future engagement.

Key Dates

Keywords

Century Therapeutics, Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, CTXR, Biotechnology, Investment, Institutional Investor